Sectors
LGND
Ligand Pharmaceuticals Incorporated
297.03
1 x 298.41
1 x 300.54
bid
ask
+
1.33
0.45%
09:41 AM
timesize
| Ytd | 57.10% | |
| 1y | 102.05% |
293.12
day range
299.99
149.00
52 week range
326.63
| Open | 295.01 | Prev Close | 295.70 | Low | 293.12 | High | 299.99 | Mkt Cap | 6.01B |
| Vol | 6.51K | Avg Vol | 355.01K | EPS | 9.11 | P/E | 32.93 | Forward P/E | 24.52 |
| Beta | 1.13 | Short Ratio | 3.28 | Inst. Own | 108.12% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 07-02 | Earning | 08-06 | 50-d Avg | 284.63 | 200-d Avg | 223.66 | 1yr Est | 343.80 |
| Income Statement | |||
| Total Revenue | 63.69M | ||
| Revenues (USD) | 63.69M | ||
| Cost of Revenue | 3.21M | ||
| Gross Profit | 60.48M | ||
| Operating Expenses | 51.89M | ||
| Research and Development Expense | 14.67M | ||
| Selling, General and Administrative Expense | 29.12M | ||
| Operating Income | 8.59M | ||
| Interest Expense | 1.75M | ||
| Income Tax Expense | 15.80M | ||
| Net Income | 48.51M | ||
| Net Income Common Stock | 48.51M | ||
| Net Income Common Stock (USD) | 48.51M | ||
| Consolidated Income | 48.51M | ||
| Earnings per Basic Share | 2.42 | ||
| Earnings per Basic Share (USD) | 2.42 | ||
| Earnings per Diluted Share | 2.22 | ||
| Earning Before Interest & Taxes (EBIT) | 66.05M | ||
| Earning Before Interest & Taxes (USD) | 66.05M | ||
| Weighted Average Shares | 20.06M | ||
| Weighted Average Shares Diluted | 21.84M | ||
| Balance Sheet | |||
| Cash and Equivalents | 1.01B | ||
| Cash and Equivalents (USD) | 1.01B | ||
| Investments | 507.93M | ||
| Investments Current | 351.06M | ||
| Investments Non-Current | 156.87M | ||
| Trade and Non-Trade Receivables | 67.01M | ||
| Current Assets | 1.46B | ||
| Total Assets | 2.19B | ||
| Debt Current | 1.08M | ||
| Total Debt | 1.13B | ||
| Current Liabilities | 46.74M | ||
| Debt Non-Current | 1.13B | ||
| Total Liabilities | 1.22B | ||
| Accumulated Retained Earnings (Deficit) | 583.25M | ||
| Accumulated Other Comprehensive Income | 4.48M | ||
| Shareholders Equity | 967.52M | ||
| Shareholders Equity (USD) | 967.52M | ||
| Assets Non-Current | 728.76M | ||
| Total Debt (USD) | 1.13B | ||
| Goodwill and Intangible Assets | 310.79M | ||
| Inventory | 10.26M | ||
| Liabilities Non-Current | 1.17B | ||
| Trade and Non-Trade Payables | 9.40M | ||
| Tax Assets | 40.03M | ||
| Tax Liabilities | 24.87M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 8.70M | ||
| Net Cash Flow from Financing | 546.43M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 891.61M | ||
| Capital Expenditure | -26.00K | ||
| Net Cash Flow - Business Acquisitions and Disposals | -2.64M | ||
| Issuance (Purchase) of Equity Shares | 62.70M | ||
| Issuance (Repayment) of Debt Securities | 484.08M | ||
| Net Cash Flow from Investing | 321.12M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 323.78M | ||
| Net Cash Flow from Operations | 24.02M | ||
| Effect of Exchange Rate Changes on Cash | 39.00K | ||
| Share Based Compensation | 13.31M | ||